Glenmark Pharmaceuticals (GPL) has received its board approval to merge its subsidiaries i.e. Glenmark Generics (GGL) and Glenmark Access (GAL) with GPL. The merger will be effected through a court approved Scheme of Amalgamation under Sections 391 to 394 and other applicable provisions of the Companies Act, 1956 (Scheme). As on date 99.33% of the share capital of GGL is being held by GPL (including 1.19% being held by GAL, a wholly owned subsidiary of GPL).For more information ✆ - 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment